Table 1 Level of evidence (LoE) of methylation markers assessed in two or more study series

 IGFBP3

TNM stages 2–3

Poor prognosis

II

13.8 (11–14)

 CDKN2A (p16)

TNM stages 1–3^b

Poor prognosis

II

11.5 (6.5–17.5)

 WNT5a

TNM stages 1–4

No influence on prognosis

II

12.5 (−)

 HPP1

TNM stage 4

Poor prognosis

II

12.5 (10–15)

 RET

TNM stage 2

Poor prognosis

II–III

15.5 (−)

 TFPA2E

TNM stages 1–4

Good prognosis

III

7.8 (5–10.5)

 Multimarker panel by Gaedcke et al. [40]

Locally advanced rectal cancer

Poor prognosis

III

12 (−)

 Multimarker panel by Kandimalla et al. [45]

TNM stage II

Poor prognosis

III

15

 HLTF

TNM stages 1–4

Poor prognosis

III–IV

15 (10–17.5)

 HPP1

TNM stages 1–4

Poor prognosis

IV

12.5 (10–15)

 EVL

TNM stages 1–4

Poor prognosis

IV

11

 CD109

TNM stages 1–4

Poor prognosis

IV

11

 NRCAM

TNM stages 1–4

Poor prognosis

IV

11

 FLNC

TNM stages 1–4

Poor prognosis

IV

11

 BNIP3

11.5 (17.5–9)

 MLH1

11.3 (10–15)

 MGMT

12 (5–17.5)

 RASSF1A

10.5 (5–17.5)

 CDKN2A (p14)

8 (5–17.5)

 APC

8.5 (5–17.5)

 CHFR

16 (17.5–14.5)

 ID4

9.5 (−)

 MYOD1

9.5 (9–10)

 SEPT9

14.75 (14.5–15)

 SFRP2

11 (10.5–11.5)

 MLH1 & CDKN2A

11 (10–12)